For CD patients, the EuropeanCrohn’s and Colitis Organisation (ECCO) recommends using any anti-TNF therapy in thefirst line17 while the American College of Gastroenterology recommends any anti-TNF or vedolizumab18 and the American Gastroenterological Association (AGA) recommends infliximab,adalimumab, or ustekinumab.19 For UC patients, AGA recommends using infliximab or vedolizumab first20 but ECCO does not overtly favor any individual treatment or class oftreatments over another as first-line therapy.21 This evidence concerns the gene TNF and colitis.